Italian NCL Registry for Batten disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial is creating a registry (a secure database) for people with a confirmed genetic diagnosis of NCL (Batten disease). The goal is to collect information over time to help researchers understand the disease better and plan future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic test that confirms you have neuronal ceroid lipofuscinosis (NCL), also known as Batten disease.
- You or your parent/guardian agree to sign a consent form to join the registry and allow your medical information to be used for research.
- You do not have any other neurodegenerative disease (like Alzheimer's or Parkinson's).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tracks how Batten disease (NCL) affects the body and how symptoms change over time. If you have a confirmed genetic (molecular) diagnosis—especially CLN2 with Brineura treatment—it may help researchers understand disease patterns and care needs.
This study looks at how Batten disease affects the body and thinking/brain function. It may help researchers better understand the condition and how symptoms change over time.
This study tests a gene therapy treatment for CLN6 Batten disease, a rare inherited condition that affects the brain and nervous system. The therapy aims to slow or stop disease progression by introducing a healthy copy of the faulty gene.
This study looks at people with CLN3 and other related forms of NCL (a childhood brain-wasting illness) to better describe symptoms and disease changes over time. You may be followed with regular check-ins, medical records, and sometimes NIH visits or sample collection.
This trial is a research registry that collects information from people who have suspected or confirmed NBIA (a rare inherited brain movement/nerve condition). It helps researchers learn more about the condition and how it affects people, which may support future studies.
This study is screening children for a rare genetic condition called CLN2 disease. It looks for signs like seizures, speech loss, and movement problems to find out how common this condition is among 6-year-olds.
Hear when a new Neuronal Ceroid Lipofuscinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.